B0,D型急性主动脉夹层的紧急胸主动脉腔内修复术
本研究比较了紧急胸主动脉腔内修复术(TEVAR)与常规外科主动脉修复术(CSAR)治疗B0,D型急性主动脉夹层(TB0,DAAD)的安全性和有效性。7例TB0,DAAD患者接受紧急TEVAR,39例A型急性主动脉夹层患者接受CSAR。TEVAR组主动脉再干预率显著高于CSAR组(28.6% vs. 0%,P < 0.01),死亡和卒中发生率无差异。结论认为在选定病例中紧急TEVAR可作为CSAR的替代方案。
要点
- TEVAR组主动脉再干预率显著高于CSAR组(28.6% vs. 0%,P < 0.01)。
- TEVAR组与CSAR组死亡和卒中发生率无差异。
- 7例TEVAR患者全部存活,5例(71.4%)在30天内免于主动脉再干预。
核心结论
- 在选定病例中,紧急TEVAR治疗TB0,DAAD可能作为CSAR的替代方案。
研究设计与样本
- 研究纳入46例超急性期(起病2天内)A型急性主动脉夹层患者,其中7例为TB0,DAAD接受紧急TEVAR,39例为TAAAD接受CSAR,比较两组结果并分析TEVAR细节。
主要发现
- TEVAR组主动脉再干预率显著高于CSAR组(28.6% vs. 0%,P < 0.01)。
- TEVAR组与CSAR组死亡和卒中发生率无差异。
- 7例TEVAR患者全部存活,5例(71.4%)在TEVAR后30天内免于主动脉再干预。
- 1例因升主动脉假腔通畅且未缩小、入口位于主动脉弓,于术后第1天行主动脉弓置换。
- 1例因近端支架移植物诱导的新入口,于术后第13天行升主动脉和横主动脉置换联合冷冻象鼻术。
关键数值与推荐
- TEVAR组主动脉再干预率28.6% vs. CSAR组0%(P < 0.01)。
- TEVAR组7例患者全部存活,5例(71.4%)在30天内免于主动脉再干预。
临床怎么用
- 作者认为,在选定病例中紧急TEVAR治疗TB0,DAAD可能作为CSAR的替代方案。
- 作者指出,术前CT准确诊断主要入口位置以排除入口、谨慎选择和释放支架移植物以预防支架移植物诱导的新入口或内漏,是手术成功、假腔重塑和良好预后的必要条件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of the present study is to clarify safety and efficacy of thoracic endovascular aortic repair (TEVAR), excluding the primary entry in the descending aorta, for type-B0,D acute aortic dissection (TB0,DAAD) (so-called retrograde type-A acute aortic dissection). METHODS: Forty-six patients with hyperacute-phase (within 2 days after the onset) type-A acute aortic dissection (TAAAD) and TB0,DAAD underwent urgent (on the admission or next day) intervention (TEVAR or conventional surgical aortic repair [CSAR]) for 2 years. Results of TEVAR for TB0,DAAD were compared with those of CSAR for TAAAD. Outcomes included 30-day mortality, aortic reintervention, and major complications (stroke and paraplegia/paraparesis). Details of TEVAR were also analyzed. RESULTS: Seven patients with TB0,DAAD and 39 patients with TAAAD underwent respectively urgent TEVAR and CSAR. Aortic reintervention was significantly more frequent in the TEVAR than CSAR group (28.6% vs. 0%, P < 0.01). There was no difference in incidence of death and stroke between the TEVAR and CSAR group. All the 7 patients survived and 5 of the 7 (71.4%) patients were relieved of aortic reintervention for 30 days following TEVAR. One patient, however, underwent aortic arch replacement on postoperative day (POD) 1 owing to the patent and nonshrinking ascending false lumen (FL). The entry existed in the aortic arch. Another patient underwent ascending and transverse aortic replacement with frozen elephant trunk on POD13 due to proximal stent graft-induced new entry irrespective of the thrombosed and shrinking ascending FL. Because of the patent and nonshrinking ascending FL, 1 patient underwent additional TEVAR for the residual entry in the distal descending thoracic aorta on POD33 and subsequently ascending aortic replacement 4 months later. No entry was detected in the ascending or transverse aorta. The ascending FL in the other 4 patients was thrombosed early, shrinking gradually, and disappeared at last following TEVAR. CONCLUSIONS: Urgent TEVAR for TB0,DAAD may be alternative to CSAR in selected cases. Accurate diagnosis of the primary entry location on preinterventional computed tomography scans for exclusion of the entry and cautious selection and delivery of a stent graft to prevent stent graft-induced new entry or endoleak are requisite for success of the procedure, remodeling of the FL, and satisfactory prognosis.
引用
- Hari Y, Takagi H. Urgent Thoracic Endovascular Aortic Repair for Type-B0,D Acute Aortic Dissection. Ann Vasc Surg. 2024. PMID: 39025222. doi:10.1016/j.avsg.2024.05.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。